- IP hearings this week
- IP trials
- IP Judicial review hearings
- IP appeals at the Federal Court of Appeal
(As published on the Federal Court and Federal Court of Appeal websites on Jan 23, 2026)
This week in IP
| Date | File No. | Type | Name | Location | Length |
| Jan 26, 2026 | T-3698-25 | M | Dnvb, Inc. V. Rita Benzacar Sales Ltd. (Trade Mark) | Toronto | 1 d |
| Jan 26, 2026 | T-2394-25 | CMC | Bcp Iv Services Station Lp V. Waypoint Coffee Inc. (Trade Mark) | Toronto | 1 h |
| Jan 26, 2026 | T-1670-19 | CMC | Millennium Funding Inc. V. Doe #1 Et Al (Copyright) | Toronto | 1 h |
| Jan 27, 2026 | T-1522-21 | MST | Ljc Apparel Llc C.o.b. Kimes Ranch V. 9277-3068 Quebec Incorporated Et Al (Trade Mark) | Montréal | 4 d |
| Jan 27, 2026 | T-673-22 | TMC | Groupe Zoom Media Inc. V. Zoom Video Communications, Inc. (Trade Mark) | Toronto | 1 h |
| Jan 27, 2026 | T-84-24 | CMC | Vero Uk Limited Et Al. V. Sherwood Innovations Inc. (Copyright) | Ottawa | 1 h |
| Jan 27, 2026 | T-3244-24 | CMC | Lego Juris A/s Et Al. V. Vanessa Phillimore (Trade Mark) | Ottawa | 1 h |
| Jan 27, 2026 | T-1583-24 | TMC | Novartis Pharmaceuticals Canada Inc. V. Apotex Inc. Et Al. (Patent - Ruxolitinib*) | Toronto | 1 h |
| Jan 27, 2026 | T-1584-24 | TMC | Novartis Pharmaceuticals Canada Inc. V. Apotex Inc. Et Al. (Patent - Ruxolitinib*) | Toronto | 1 h |
| Jan 29, 2026 | A-132-25 | APP | 6035558 Canada Inc. Et Al V. Unilin Beheer B.v. Et Al (Patent) | Ottawa | 0 |
| Jan 29, 2026 | T-205-25 | M | Union Square Hospitality Group, Llc Et Al. V. Aquilini Restaurants Limited P (Trade Mark) | Ottawa | 2 h |
| Jan 30, 2026 | T-1637-25 | M | Trademark Building Products Ltd. V. Window World International Llc. (unknown) | Toronto | 2 h |
| Jan 30, 2026 | T-1644-25 | M | Window World International, Llc V. Trademark Building Products Ltd. (Trade Mark) | Toronto | 2 h |
| Jan 30, 2026 | T-1645-25 | M | Window World International, Llc V. Trademark Building Products Ltd. (Trade Mark) | Toronto | 2 h |
| Jan 30, 2026 | T-2774-25 | M | Window World International, Llc V. Trademark Building Products Ltd. (Trade Mark) | Toronto | 2 h |
| Jan 30, 2026 | T-7-25 | M | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada (Patent - Apalutamide*) | Toronto | 1 d |
| Jan 30, 2026 | T-8-25 | M | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 1 d |
| Jan 30, 2026 | T-9-25 | M | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 1 d |
| Jan 30, 2026 | T-386-21 | CMC | 2572495 Ontario Inc. V. Vacuum Specialists (1985) Ltd. Et Al. (Copyright) | Edmonton | 1 h |
Return to top.
Scheduled IP Trials
| Date | File No. | Name | Location | Length |
| Feb 23, 2026 | T-1308-24 | Taiho Pharmaceutical Co., Ltd. Et Al. V. Pharmascience Inc. (Patent - Trifluridine*) | Toronto | 12 d |
| Feb 23, 2026 | T-1309-24 | Taiho Pharmaceutical Co., Ltd. Et Al. V. Pharmascience Inc. (Patent - Trifluridine*) | Toronto | 12 d |
| Feb 25, 2026 | T-886-21 | The Toronto-dominion Bank V. Thomas John Dyas Et Al (Trademark) | Toronto | 2 d |
| Mar 2, 2026 | T-673-22 | Groupe Zoom Media Inc. V. Zoom Video Communications, Inc. (Trade Mark) | Toronto | 5 d |
| Mar 9, 2026 | T-1346-21 | Federation Of Asian Canadians Toronto V. Asialicious Holdings Inc. Et Al. (Trade Mark) | Toronto | 4 d |
| Mar 11, 2026 | T-673-22 | Groupe Zoom Media Inc. V. Zoom Video Communications, Inc. (Trade Mark) | Toronto | 2 d |
| Mar 16, 2026 | T-1308-24 | Taiho Pharmaceutical Co., Ltd. Et Al. V. Pharmascience Inc. (Patent - Trifluridine*) | Toronto | 2 d |
| Mar 16, 2026 | T-1309-24 | Taiho Pharmaceutical Co., Ltd. Et Al. V. Pharmascience Inc. (Patent - Trifluridine*) | Toronto | 2 d |
| Mar 18, 2026 | T-1346-21 | Federation Of Asian Canadians Toronto V. Asialicious Holdings Inc. Et Al. (Trade Mark) | Toronto | 1 d |
| Mar 23, 2026 | T-1662-24 | Eisai Limited And Eisai R&d Et Al. V. Dr. Reddy's Laboratories Ltd. (Patent - Lenvatinib*) | Toronto | 8 d |
| Apr 15, 2026 | T-1662-24 | Eisai Limited And Eisai R&d Et Al. V. Dr. Reddy's Laboratories Ltd. (Patent - Lenvatinib*) | Toronto | 2 d |
| May 25, 2026 | T-2593-24 | Janssen Inc. Et Al. V. Pharmascience Inc. (Patent - Macitentan*) | Toronto | 4 d |
| Jun 1, 2026 | T-2593-24 | Janssen Inc. Et Al. V. Pharmascience Inc. (Patent - Macitentan*) | Toronto | 2 d |
| Jun 8, 2026 | T-2593-24 | Janssen Inc. Et Al. V. Pharmascience Inc. (Patent - Macitentan*) | Toronto | 2 d |
| Aug 17, 2026 | T-7-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada (Patent - Apalutamide*) | Toronto | 4 d |
| Aug 17, 2026 | T-8-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 4 d |
| Aug 17, 2026 | T-9-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 4 d |
| Aug 24, 2026 | T-7-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada (Patent - Apalutamide*) | Toronto | 4 d |
| Aug 24, 2026 | T-8-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 4 d |
| Aug 24, 2026 | T-9-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 4 d |
| Aug 31, 2026 | T-7-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada (Patent - Apalutamide*) | Toronto | 4 d |
| Aug 31, 2026 | T-8-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 4 d |
| Aug 31, 2026 | T-9-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 4 d |
| Sep 8, 2026 | T-7-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada (Patent - Apalutamide*) | Toronto | 3 d |
| Sep 8, 2026 | T-8-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 3 d |
| Sep 8, 2026 | T-9-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 3 d |
| Sep 8, 2026 | T-75-25 | Boehringer Ingelheim(canada) Ltd. Et Al V.laboratoire Riva Inc (Patent - Empagliflozin*) | Toronto | 4 d |
| Sep 8, 2026 | T-1142-18 | Navtech Inc. V. Chantier Davie Canada Inc. (unknown) | Québec | 4 d |
| Sep 14, 2026 | T-75-25 | Boehringer Ingelheim(canada) Ltd. Et Al V.laboratoire Riva Inc (Patent - Empagliflozin*) | Toronto | 4 d |
| Sep 14, 2026 | T-1567-24 | Justin Stitches Inc. V. Makers Holdings Inc. (Trade Mark) | Vancouver | 5 d |
| Sep 16, 2026 | T-1142-18 | Navtech Inc. V. Chantier Davie Canada Inc. (unknown) | Québec | 2 d |
| Sep 21, 2026 | T-75-25 | Boehringer Ingelheim(canada) Ltd. Et Al V.laboratoire Riva Inc (Patent - Empagliflozin*) | Toronto | 4 d |
| Sep 28, 2026 | T-75-25 | Boehringer Ingelheim(canada) Ltd. Et Al V.laboratoire Riva Inc (Patent - Empagliflozin*) | Toronto | 2 d |
| Oct 19, 2026 | T-451-20 | Kobold Corporation Et Al. V. Ncs Multistage Inc. (Patent) | Calgary | 4 d |
| Oct 19, 2026 | T-1059-22 | Seylynn (north Shore) Development Limited Partnership V. Denna Homes Group (Trade Mark) | Vancouver | 10 d |
| Oct 26, 2026 | T-451-20 | Kobold Corporation Et Al. V. Ncs Multistage Inc. (Patent) | Calgary | 4 d |
| Nov 4, 2026 | T-1059-22 | Seylynn (north Shore) Development Limited Partnership V. Denna Homes Group (Trade Mark) | Vancouver | 2 d |
| Nov 18, 2026 | T-451-20 | Kobold Corporation Et Al. V. Ncs Multistage Inc. (Patent) | Calgary | 2 d |
| Nov 23, 2026 | T-742-25 | Salix Pharmaceuticals, Inc. V. Sandoz Canada Inc. (Patent) | Toronto | 8 d |
| Nov 23, 2026 | T-887-25 | Boehringer Ingelheim (canada) Ltd Et Al V. Auro Pharma Inc (Patent - Empagliflozin*) | To be determined (TrialJA) | 13 d |
| Nov 23, 2026 | T-1818-23 | The Bank Of Nova Scotia V. Invesco Canada Ltd. (Trade Mark) | Toronto | 5 d |
| Nov 23, 2026 | T-3388-24 | Aralez Pharmaceuticals Canada Inc. V. Laboratoire Riva Inc. Et Al. (Patent - Diclofenac*) | Toronto | 10 d |
| Nov 23, 2026 | T-3386-24 | Aralez Pharmaceuticals Canada Inc. V. Laboratoire Riva Inc. Et Al. (Patent - Diclofenac*) | Toronto | 10 d |
| Dec 2, 2026 | T-1818-23 | The Bank Of Nova Scotia V. Invesco Canada Ltd. (Trade Mark) | Toronto | 2 d |
| Dec 7, 2026 | T-742-25 | Salix Pharmaceuticals, Inc. V. Sandoz Canada Inc. (Patent) | Toronto | 2 d |
| Dec 17, 2026 | T-887-25 | Boehringer Ingelheim (canada) Ltd Et Al V. Auro Pharma Inc (Patent - Empagliflozin*) | To be determined (TrialJA) | 2 d |
| Jan 18, 2027 | T-1792-21 | Tanja Porcnik V. Cato Institute Et Al. (Copyright) | Toronto | 4 d |
| Jan 25, 2027 | T-1792-21 | Tanja Porcnik V. Cato Institute Et Al. (Copyright) | Toronto | 4 d |
| Feb 1, 2027 | T-1627-25 | Hoffmann-la Roche Limited Et Al. V. Shanghai Henlius Biotech, Inc. Et Al. (Patent - Pertuzumab*) | Toronto | 4 d |
| Feb 3, 2027 | T-1792-21 | Tanja Porcnik V. Cato Institute Et Al. (Copyright) | Toronto | 2 d |
| Feb 8, 2027 | T-1627-25 | Hoffmann-la Roche Limited Et Al. V. Shanghai Henlius Biotech, Inc. Et Al. (Patent - Pertuzumab*) | Toronto | 4 d |
| Feb 15, 2027 | T-377-25 | Emergent Operations Ireland Limited Et Al. V. Padagis Isreal Pharmaceuticals (Patent - Naloxone*) | Toronto | 4 d |
| Feb 16, 2027 | T-1245-25 | Boehringer Ingelheim (canada) Ltd. Et Al. V. Auro Pharma Inc. (Patent - Empagliflozin*) | To be determined (TrialJA) | 4 d |
| Feb 16, 2027 | T-1627-25 | Hoffmann-la Roche Limited Et Al. V. Shanghai Henlius Biotech, Inc. Et Al. (Patent - Pertuzumab*) | Toronto | 2 d |
| Feb 22, 2027 | T-377-25 | Emergent Operations Ireland Limited Et Al. V. Padagis Isreal Pharmaceuticals (Patent - Naloxone*) | Toronto | 4 d |
| Feb 22, 2027 | T-1245-25 | Boehringer Ingelheim (canada) Ltd. Et Al. V. Auro Pharma Inc. (Patent - Empagliflozin*) | To be determined (TrialJA) | 4 d |
| Mar 2, 2027 | T-377-25 | Emergent Operations Ireland Limited Et Al. V. Padagis Isreal Pharmaceuticals (Patent - Naloxone*) | Toronto | 2 d |
| Mar 3, 2027 | T-1245-25 | Boehringer Ingelheim (canada) Ltd. Et Al. V. Auro Pharma Inc. (Patent - Empagliflozin*) | To be determined (TrialJA) | 2 d |
| Mar 10, 2027 | T-2504-25 | Novartis Pharmaceuticals Canada Inc Et Al. V. Apotex Inc. (Patent) | To be determined (TrialJA) | 10 d |
| Mar 10, 2027 | T-2505-25 | Novartis Pharmaceuticals Canada Inc Et Al. V. Apotex Inc. (Patent - Trametinib*) | To be determined (TrialJA) | 10 d |
| Mar 30, 2027 | T-2504-25 | Novartis Pharmaceuticals Canada Inc Et Al. V. Apotex Inc. (Patent) | To be determined (TrialJA) | 2 d |
| Mar 30, 2027 | T-2505-25 | Novartis Pharmaceuticals Canada Inc Et Al. V. Apotex Inc. (Patent - Trametinib*) | To be determined (TrialJA) | 2 d |
| Apr 5, 2027 | T-2529-25 | Nuvo Pharmaceuticals (ireland) Designated Activity Company V. Pharmascience (Patent - Naproxen*) | Toronto | 4 d |
| Apr 12, 2027 | T-2529-25 | Nuvo Pharmaceuticals (ireland) Designated Activity Company V. Pharmascience (Patent - Naproxen*) | Toronto | 4 d |
| Apr 19, 2027 | T-3096-25 | Astrazeneca Canada Inc. Et Al. V. Cipla Ltd. (Patent - Olaparib*) | To be determined (TrialJA) | 4 d |
| Apr 21, 2027 | T-2529-25 | Nuvo Pharmaceuticals (ireland) Designated Activity Company V. Pharmascience (Patent - Naproxen*) | Toronto | 2 d |
| Apr 26, 2027 | T-3096-25 | Astrazeneca Canada Inc. Et Al. V. Cipla Ltd. (Patent - Olaparib*) | To be determined (TrialJA) | 4 d |
| May 10, 2027 | T-3096-25 | Astrazeneca Canada Inc. Et Al. V. Cipla Ltd. (Patent - Olaparib*) | To be determined (TrialJA) | 2 d |
| May 10, 2027 | T-3206-25 | Leo Pharma Inc. Et Al. V. Glenmark Pharmaceuticals Canada Inc. (Patent - Calcipotriol*) | Toronto | 4 d |
| May 17, 2027 | T-3206-25 | Leo Pharma Inc. Et Al. V. Glenmark Pharmaceuticals Canada Inc. (Patent - Calcipotriol*) | Toronto | 3 d |
| May 25, 2027 | T-3206-25 | Leo Pharma Inc. Et Al. V. Glenmark Pharmaceuticals Canada Inc. (Patent - Calcipotriol*) | Toronto | 2 d |
| May 31, 2027 | T-3181-25 | Eisai Limited Et Al. V. Mint Pharmaceuticals Inc. (Patent - Perampanel*) | Toronto | 4 d |
| Jun 7, 2027 | T-3181-25 | Eisai Limited Et Al. V. Mint Pharmaceuticals Inc. (Patent - Perampanel*) | Toronto | 4 d |
| Jun 16, 2027 | T-3181-25 | Eisai Limited Et Al. V. Mint Pharmaceuticals Inc. (Patent - Perampanel*) | Toronto | 2 d |
| Jun 22, 2027 | T-3922-25 | Astrazeneca Canada Inc. Et Al. V. Natco Pharma (canada) Inc. (Patent - Olaparib*) | Ottawa | 9 d |
| Jun 28, 2027 | T-3739-25 | Novartis Pharmaceuticals Canada Inc V. Pharmascience Inc. Et Al. (Patent - Ruxolitinib*) | To be determined (TrialJA) | 3 d |
| Jul 2, 2027 | T-3739-25 | Novartis Pharmaceuticals Canada Inc V. Pharmascience Inc. Et Al. (Patent - Ruxolitinib*) | To be determined (TrialJA) | 5 d |
| Jul 7, 2027 | T-3922-25 | Astrazeneca Canada Inc. Et Al. V. Natco Pharma (canada) Inc. (Patent - Olaparib*) | Ottawa | 2 d |
| Jul 15, 2027 | T-3739-25 | Novartis Pharmaceuticals Canada Inc V. Pharmascience Inc. Et Al. (Patent - Ruxolitinib*) | To be determined (TrialJA) | 2 d |
| Aug 9, 2027 | T-4459-25 | Novartis Pharmaceuticals Canada Inc. V. Dr. Reddy's Laboratories Ltd. Et Al. (Patent - Ruxolitinib*) | Ottawa | 10 d |
| Aug 26, 2027 | T-4459-25 | Novartis Pharmaceuticals Canada Inc. V. Dr. Reddy's Laboratories Ltd. Et Al. (Patent - Ruxolitinib*) | Ottawa | 2 d |
| Sep 7, 2027 | T-4796-25 | Lundbeck Canada Inc. Et Al. V. Teva Canada Limited (Patent - Vortioxetine*) | Ottawa | 9 d |
| Sep 7, 2027 | T-4989-25 | Lundbeck Canada Inc. Et Al. V. Zydus Lifesciences Limited Et Al. (Patent - Vortioxetine*) | Ottawa | 9 d |
| Sep 20, 2027 | T-704-25 | Genevant Sciences Gmbh Et Al. V. Moderna Biopharma Canada Corp Et Al. (Patent) | Toronto | 4 d |
| Sep 23, 2027 | T-4796-25 | Lundbeck Canada Inc. Et Al. V. Teva Canada Limited (Patent - Vortioxetine*) | Ottawa | 2 d |
| Sep 23, 2027 | T-4989-25 | Lundbeck Canada Inc. Et Al. V. Zydus Lifesciences Limited Et Al. (Patent - Vortioxetine*) | Ottawa | 2 d |
| Sep 27, 2027 | T-704-25 | Genevant Sciences Gmbh Et Al. V. Moderna Biopharma Canada Corp Et Al. (Patent) | Toronto | 3 d |
| Oct 4, 2027 | T-704-25 | Genevant Sciences Gmbh Et Al. V. Moderna Biopharma Canada Corp Et Al. (Patent) | Toronto | 4 d |
| Oct 19, 2027 | T-704-25 | Genevant Sciences Gmbh Et Al. V. Moderna Biopharma Canada Corp Et Al. (Patent) | Toronto | 3 d |
Return to top.
Scheduled Judicial Review Hearings
| Date | File No. | Name | Type | Location | Length |
| Feb 10, 2026 | T-1961-25 | Companionship Of The Sacred Vine Inc. V. Minister Of Health Of Canada Et Al | S. 18.1 Application for Judicial Review | Calgary | 3 h |
| Feb 18, 2026 | T-28-24 | Grc Food Services Ltd. V. Chocoladefabriken Lindt & Sprungli Ag | Trade Mark - Appeal of a decision of the Registrar | Vancouver | 1 d |
Return to top.
Scheduled IP Appeals
| Date | File No. | Name | Type | Location |
| Jan 20, 2026 | A-242-25 | Marrand Auto Inc. V. Toyota Jidosha Kabushiki Kaisha Et Al | Appeal (S.27 - Interloc.) - Trade-marks Act [from T-627-23 - Trade Mark - Passing Off] | Vancouver |
| Jan 21, 2026 | A-193-24 | Wanakome Inc V. Eric Martin Et Al. | Appeal (S.27 - Final) - Trade-marks Act | Montréal |
| Jan 22, 2026 | A-274-24 | Ap&c Advanced Powders & Coatings Inc. V. Tekna Plasma Systems Inc. | Appeal (S.27 - Interloc.) - Patent Act [from T-126-19 - Patent Impeachment] | Montréal |
| Jan 29, 2026 | A-132-25 | 6035558 Canada Inc. Et Al V. Unilin Beheer B.v. Et Al | Appeal (S.27 - Interloc.) - Patent Act [from T-116-19 - Patent Infringement] | Ottawa |
* Medicinal ingredients are based on automated analysis and should not be relied upon.
Return to top.